British National Formulary February 2025 Update

This update contains 1 significant change, 3 dose changes, 4 new monographs and 2 deleted monographs.

Significant Changes:

• Wegovy® (semaglutide): new indication and dose for cardiovascular risk reduction.

Dose Changes:

• Glyceryl trinitrate [update to dosing for treatment of angina using sublingual tablets or spray].
• Medical emergencies in the community [update to dosing of glyceryl trinitrate for acute coronary syndromes].
• Ozempic® (semaglutide) [update to indications and dosing].

New Monographs:

• Fruzaqla® [fruquintinib].
• Kisunla® [donanemab].
• Loargys® [pegzilarginase].
• Yorvipath® [palopegteriparatide].

Deleted Monographs: Co-flumactone; Co-simalcite.